Victory Square Health Announces Update to Previous News Release

Victory Square Health Announces Order of 2 Million (2,000,000) UNITS for its Safetest Covid-19 Test in Brazil.

VANCOUVER, British Columbia, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (“VS Health” or the "Company") – a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) announces an update to its press release entitled “Victory Square Health Provides a Progress Update on its Covid-19 Test” issued September 21, 2020 (the “September 22 Press Release”).

The Company received an order of 2 Million (2,000,000) UNITS of its Safetest Covid-19 test in Brazil. This update does not change any other amounts or information reported in the September 21 Press Release.

Safetest Covid-19 test enables the user to verify whether one is currently infected, has been infected or has never been infected with Covid-19. The Company this past month has:

• Company received an order of 2 Million (2,000,000) UNITS for its Safetest Covid-19 test in Brazil.
• VS Health received the CE designation from the EU competent authority of Belgium for Safetest Elisa antibody test for distribution, sale, and usage throughout the 27 countries in the European Union.
• VS Health received Brazilian ANIVSA approval for Safetest ELISA antibody test for distribution, sale, and usage throughout Brazil and export to Mercosur Countries (Argentina, Paraguay, Uruguay and Venezuela).
• VS Health received USDA permission to commence marketing, sales and distribution of Safetest Covid-19 Antibody Elisa Test under EUA.
• VS Health was the first company to be approved in the Ideiagov program supported by the São Paulo State Government for immediate trials and application in the State.
• VS Health increased monthly production of Covid-19 Rapid Tests by an additional 5,000,000 Test Kits to meet increased demand.
• Safetest Covid-19 IgG /IgM has demonstrated to the U.S. FDA, Brazilian, and European Union authorities 93.3% sensitivity and 98.7% specificity.
  

The Company continues to present its product for and receive new approvals from Health Authorities and Governments globally. Victory Square Health’s strategy is to receive ongoing global approvals from Governments followed by the Company’s implementation of immediate supply, manufacturing and distribution channels being set up with new partners in those approved jurisdictions/countries for rapid manufacturing, distribution and sales of its product.